Alkynes

Taronis Announces Third Quarter Earning Call

Retrieved on: 
Tuesday, November 19, 2019
Industrial gases, Chemistry, Fuel gas, Energy development, Physical sciences, Chemical substances, Acetylene, Alkynes, Fuel, Hydrogen technologies

Taronis Technologies, Inc. (TRNX) owns a patented plasma arc technology that enables two primary end use applications for fuel generation and water decontamination.

Key Points: 
  • Taronis Technologies, Inc. (TRNX) owns a patented plasma arc technology that enables two primary end use applications for fuel generation and water decontamination.
  • The Companys fuel technology enables a wide use of hydrocarbon feedstocks to be readily converted to fossil fuel substitutes.
  • The Company currently markets a proprietary metal cutting fuel that is highly competitive with acetylene.
  • The Companys technology can also be implemented for the decontamination of waste water, including sterilizing water, eradicating all pathogens.

Acetylene Forecasts to 2024: Metalworking Industry to Dominate the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, July 8, 2019
Professional services, Consulting, Acetylene, Alkynes, Fields of mathematics, Compound annual growth rate, Metalworking, Chemistry, Physical sciences

The global acetylene market is expected to record a CAGR of over 2.5% during the forecast period 2019-2024.

Key Points: 
  • The global acetylene market is expected to record a CAGR of over 2.5% during the forecast period 2019-2024.
  • The major factor driving the market studied is the growing demand from the power and chemical industry.
  • The Metalworking Industry dominated the market in 2018, and it is expected to experience growth during the forecast period, owing to the increasing metal working activities across the world.
  • With the growing metalworking applications, the market for acetylene is projected to increase over the forecast period.

Tarceva - Drug Insight Study, 2019-2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 12, 2019
Health, Pharmaceutical, Organic compounds, Chemical compounds, Astellas Pharma, Alkynes, Amines, Erlotinib, Ethers, Quinazolines, SWOT analysis, SWOT, Chemistry

The "Tarceva - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tarceva - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Tarceva - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of the Tarceva covering the historical global sales and also provides the Tarceva sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Tarceva and emerging therapies in this space.

mGlu5 Antagonist Pipeline Insight, 2019 Report Featuring Seaside Therapeutics, Allergan, Gedeon Richter, Novartis, & CT Laboratories - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2019
Health, Clinical trials, Pharmaceutical, Drug pipeline, Food and Drug Administration, Alkynes, Pyridines

The "mGlu5 Antagonist -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mGlu5 Antagonist -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • mGlu5 Antagonist - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across mGlu5 Antagonist development.
  • Descriptive coverage of pipeline development activities for mGlu5 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
  • The report assesses the active mGlu5 Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

Retrieved on: 
Friday, March 22, 2019
RTT, Health, Alkynes, Antifungals, Novartis, Terbinafine, Articles, Companies, Onychomycosis, Bayer, Pharmaceutical industry in China

STOCKHOLM, March 22, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in Europe.

Key Points: 
  • STOCKHOLM, March 22, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in Europe.
  • Phase 3 studies for MOB-015are progressing in Europe and North America evaluating the efficacy and safety of MOB-015, Moberg Pharma's proprietary topical formulation of terbinafine.
  • The enrollment to the European study has now been completed with 452 patients randomized at 48 sites in Europe.
  • Moberg Pharma has entered two license agreements for the commercialization of MOB-015 with Bayer AG in Europe and Cipher Pharmaceuticals in Canada.

Azilect - Drug Insight, 2019-2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 18, 2019
Health, Pharmaceutical, Alkynes, Nootropics, Rasagiline, SWOT

The "Azilect - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Azilect - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Azilect Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of the Azilect covering the historical global sales and also provides the Azilect sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Azilect and emerging therapies in this space.

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis

Retrieved on: 
Tuesday, September 18, 2018
RTT, Medicine, Holomycota, Antifungals, Alkynes, Novartis, Terbinafine, Dermatophyte, Onychomycosis, Clinical medicine, Moberg, Mycosis

MISSISSAUGA,ON, Sept. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has acquired the exclusive Canadian rights to commercialize, promote, sell and distribute MOB-015 from Moberg Pharma (OMX:MOB) ("Moberg").

Key Points: 
  • MISSISSAUGA,ON, Sept. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has acquired the exclusive Canadian rights to commercialize, promote, sell and distribute MOB-015 from Moberg Pharma (OMX:MOB) ("Moberg").
  • MOB-015 is a topical formulation of terbinafine for treatment of onychomycosis, a common and destructive nail infection caused predominately by dermatophyte fungi.
  • Moberg Pharma estimates the global peak sales potential for MOB-015 to be in the range of USD $250-$500 million.
  • MOB-015 is an internally developed topical formulation of terbinafine based on Moberg Pharma's experience from its leading OTC product Kerasal Nail/Emtrix.